

AMENDMENTS TO THE CLAIMS

1. (previously presented) A method of inhibiting gastrointestinal absorption of phosphorous in a person, comprising: orally administering to a person in need thereof a quantity of a pharmaceutical composition of calcium glutarate sufficient to bind with phosphorous in the gastrointestinal tract, wherein said pharmaceutical composition inhibits gastrointestinal absorption of phosphorous in the person, and wherein said composition does not contain non-glutarate calcium salts in amounts sufficient to neutralize gastric acidity.
2. (Original) The method according to claim 1 wherein the calcium glutarate is present in an amount sufficient to provide between about 400mg to about 1500mg of calcium as calcium glutarate.
3. (Original) The method according to claim 1 wherein the calcium glutarate is in tablet form.
4. (Original) The method according to claim 1 wherein the calcium glutarate is in gelatin capsule form.
5. (Original) The method according to claim 1 wherein the calcium glutarate is in effervescent form.
6. (Original) The method according to claim 1 wherein the calcium glutarate is in liquid form.
7. (previously presented) A method of inhibiting gastrointestinal absorption of phosphorous in an individual, comprising: orally administering to a person in need thereof a quantity of a pharmaceutical composition of calcium glutarate sufficient to bind with phosphorous in the gastrointestinal tract at a mealtime, wherein said pharmaceutical composition inhibits gastrointestinal absorption of phosphorous in the person, and wherein said

composition does not contain non-glutarate calcium salts in amounts sufficient to neutralize gastric acidity.

8. (Original) The method according to claim 7 wherein the quantity of calcium glutarate is present in an amount sufficient to provide between about 400mg to about 1500mg of calcium as calcium glutarate.
9. (Original) The method according to claim 7 wherein the quantity of calcium glutarate is in tablet form.
10. (Original) The method according to claim 7 wherein the quantity of calcium glutarate is in gelatin form.
11. (Original) The method according to claim 7 wherein the quantity of calcium glutarate is in effervescent form.
12. (Original) The method according to claim 7 wherein the calcium glutarate is in liquid form.
13. (currently amended) A pharmaceutical therapeutic composition in solid, gel, or effervescent oral dosage form for controlling phosphate retention in patients having need for reduced absorption of dietary phosphate, said oral dosage form composition comprising sufficient calcium glutarate to bind with phosphorous in the gastrointestinal tract, and a pharmaceutically acceptable excipient for said oral dosage form, wherein said solid, gel, or effervescent oral dosage form comprises a single dose, and wherein said composition does not contain non-glutarate calcium salts in amounts sufficient to neutralize gastric acidity.
14. (original) The therapeutic composition according to claim 13 wherein the quantity of calcium glutarate is present in an amount sufficient to provide between about 400mg to about 1500mg of calcium as calcium glutarate.

15. (Original) The therapeutic composition according to claim 13 wherein the quantity of calcium glutarate is in tablet form.
16. (Original) The therapeutic composition according to claim 13 wherein the quantity of calcium glutarate is in gelatin form.
17. (Original) The therapeutic composition according to claim 13 wherein the calcium glutarate is in effervescent form.
18. (cancelled)
19. (currently amended) An orally administerable pharmaceutical composition for use in the treatment of hyperphosphatemia and for preventing the formation of phosphate- and oxalate-containing kidney stones in humans which comprises as the principal active ingredient a therapeutically effective amount of calcium glutarate sufficient to bind with phosphorous in the gastrointestinal tract combined with a pharmaceutically acceptable carrier, wherein said pharmaceutical composition ~~oral dosage form~~ comprises a solid, gel, or effervescent oral dosage of a single dose, and wherein said composition does not contain non-glutarate calcium salts in amounts sufficient to neutralize gastric acidity.
20. (Original) A pharmaceutical composition according to claim 19 particularly adapted for treating hyperphosphatemia and for preventing the formation of phosphate- and oxalate-containing kidney stones in which the calcium glutarate is present in the amount of about 400mg to about 1500mg of calcium as calcium glutarate.
21. (Original) A method of treating hyperphosphatemia and for preventing the formation of phosphate- and oxalate-containing kidney stones in humans which comprises orally administering to a person in need thereof a pharmaceutical composition according to claim 19.

22. (Original) A method of treating hyperphosphatemia and for preventing the formation of phosphate- and oxalate-containing kidney stones in humans which comprises orally administering to a person in need thereof a pharmaceutical composition according to claim 20.
23. (Original) A method of treating hyperphosphatemia and for preventing the formation of phosphate-containing kidney stones in humans which comprises orally administering to a person in need thereof a pharmaceutical composition according to claim 19.
24. (Original) A method of treating hyperphosphatemia and for preventing the formation of phosphate-containing kidney stones in humans which comprises orally administering to a person in need thereof a pharmaceutical composition according to claim 20.
25. (currently amended) A pharmaceutical compound for treating hyperphosphatemia and for preventing the formation of phosphate-containing kidney stones in humans of the formula:
pharmaceutical grade $[\text{OOC}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COO}]\text{Ca}$ in an amount sufficient to inhibit gastrointestinal absorption of phosphorous in a person, and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition oral dosage form comprises a solid, gel, or effervescent oral dosage of a single dose, and wherein said composition does not contain non-glutarate calcium salts in amounts sufficient to neutralize gastric acidity.
26. (Previously presented) A method of treating hyperphosphatemia and for preventing the formation of phosphate-containing kidney stones in mammals, which comprises administering to a mammal a phosphorous binding amount of the compound of claim 25.
27. (Original) A method of treating hyperphosphatemia, which comprises administering to a mammal a hyperphosphatemia treating amount of the compound of claim 25.

28. (Original) A therapeutic composition according to claim 25 wherein the quantity of calcium glutarate is present in an amount sufficient to provide between about 400mg to about 1500mg of calcium as calcium glutarate.
29. (Original) The therapeutic composition according to claim 25 wherein the quantity of calcium glutarate is in tablet form.
30. (Original) The therapeutic composition according to claim 25 wherein the quantity of calcium glutarate is in gelatin form.
31. (Original) The therapeutic composition according to claim 25 wherein the calcium glutarate is in effervescent form.
32. (cancelled)